Lorence Kim Biography and Net Worth

Dr. Kim is an accomplished healthcare industry leader who has made significant contributions across the biotechnology and financial industries during his career at Moderna and Goldman Sachs. He has extensive operational expertise and an extraordinary track record in raising capital for high-growth health care companies.

Dr. Kim is a co-founder and managing partner of Ascenta Capital. Previously, he served as a venture partner at Third Rock Ventures. Dr. Kim was previously the chief financial officer of Moderna, Inc., where over six years from April 2014 to June 2020, he was instrumental in raising $4.4 billion in capital to support the company’s platform efforts in mRNA therapeutics and the development of its pipeline of more than 20 drug candidates spanning oncology and other therapeutic areas. Before joining Moderna, Dr. Kim had a highly productive 14-year career at Goldman Sachs, where he advised numerous companies as a managing director and co-head of biotechnology investment banking.

Dr. Kim currently serves on the boards of directors of AmerisourceBergen Corporation, ADARx, Inc., Flare Therapeutics, Inc., and Abata Therapeutics, Inc. and previously served on the board of directors of Seres Therapeutics, Inc. He is also on the Board of Governors of the American Red Cross. Dr. Kim received an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. in healthcare management from the Wharton School of the University of Pennsylvania and an A.B. in biochemical sciences from Harvard University.

What is Lorence H. Kim's net worth?: The estimated net worth of Lorence H. Kim is at least $2.18 million as of July 22nd, 2022. Dr. Kim owns 60,500 shares of Revolution Medicines stock worth more than $2,175,580 as of April 28th. This net worth approximation does not reflect any other assets that Dr. Kim may own. Learn More about Lorence H. Kim's net worth.
How do I contact Lorence H. Kim?: The corporate mailing address for Dr. Kim and other Revolution Medicines executives is 700 Saginaw Drive, Redwood City CA, 94063. Revolution Medicines can also be reached via phone at 650-481-6801 and via email at [email protected]. Learn More on Lorence H. Kim's contact information.
Has Lorence H. Kim been buying or selling shares of Revolution Medicines?: Lorence H. Kim has not been actively trading shares of Revolution Medicines over the course of the past ninety days. Most recently, on Friday, July 22nd, Lorence H. Kim bought 50,000 shares of Revolution Medicines stock. The stock was acquired at an average cost of $20.00 per share, with a total value of $1,000,000.00. Following the completion of the transaction, the director now directly owns 60,500 shares of the company's stock, valued at $1,210,000. Learn More on Lorence H. Kim's trading history.
Who are Revolution Medicines' active insiders?: Revolution Medicines' insider roster includes Jack Anders (Insider), Jeff Cislini (General Counsel), Mark Goldsmith (Insider), Margaret Horn (COO), Stephen Kelsey (President, Research & Development), Lorence Kim (Director), Vincent Miller (Director), Thilo Schroeder (Director), Peter Svennilson (Director), Xiaolin Wang (Insider), and Barbara Weber (Director). Learn More on Revolution Medicines' active insiders.
Are insiders buying or selling shares of Revolution Medicines?: In the last twelve months, insiders at the sold shares 34 times. They sold a total of 236,176 shares worth more than $7,455,013.90. The most recent insider tranaction occured on April, 10th when Director Sushil Patel sold 2,155 shares worth more than $79,735.00. Insiders at Revolution Medicines own 8.5% of the company. Learn More about insider trades at Revolution Medicines.
Information on this page was last updated on 4/10/2024.

Lorence H. Kim Insider Trading History at Revolution Medicines

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/22/2022	Buy	50,000	$20.00	$1,000,000.00	60,500

Lorence H. Kim Buying and Selling Activity at Revolution Medicines

Revolution Medicines Company Overview

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Today's Range

Now: $35.96

$34.65

$36.36

50 Day Range

MA: $32.33

$29.05

$37.41

2 Week Range

Now: $35.96

$15.44

$38.73

Volume

1,213,741 shs

Average Volume

1,333,327 shs

Market Capitalization

$5.92 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.54

Biden replacement revealed?

From Paradigm Press | Ad

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report